Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases

[1]  J. Cheville,et al.  New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia , 2021, Modern Pathology.

[2]  J. Cheville,et al.  Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia , 2021, Modern Pathology.

[3]  S. Ferrari,et al.  Author contributions , 2021 .

[4]  G. De Velasco,et al.  Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome , 2020, Modern Pathology.

[5]  T. Antic,et al.  Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous , 2020, The American journal of surgical pathology.

[6]  K. Trpkov,et al.  ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification , 2020, Cancers.

[7]  R. Alaghehbandan,et al.  Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach , 2019, Cancers.

[8]  R. Shah,et al.  “Renal Cell Carcinoma With Leiomyomatous Stroma” Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity , 2019, The American journal of surgical pathology.

[9]  M. Bonert,et al.  High‐grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex , 2019, Histopathology.

[10]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[11]  K. Trpkov,et al.  New and emerging renal entities: a perspective post‐WHO 2016 classification , 2019, Histopathology.

[12]  V. Reuter,et al.  Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm , 2019, The American journal of surgical pathology.

[13]  M. Bonert,et al.  “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases , 2018, Virchows Archiv.

[14]  James X. Sun,et al.  Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer , 2018, Oncotarget.

[15]  P. Argani,et al.  Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum , 2018, The American journal of surgical pathology.

[16]  Lauren L. Ritterhouse,et al.  Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations? , 2018, The American journal of surgical pathology.

[17]  M. Tretiakova.  Eosinophilic solid and cystic renal cell carcinoma mimicking epithelioid angiomyolipoma: series of 4 primary tumors and 2 metastases. , 2018, Human pathology.

[18]  J. Swensen,et al.  Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. , 2018, European journal of cancer.

[19]  J. Marshall,et al.  Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients , 2018, Cancer medicine.

[20]  B. Delahunt,et al.  Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. , 2017, Human pathology.

[21]  D. Berney,et al.  Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity , 2017, The American journal of surgical pathology.

[22]  N. Schultz,et al.  Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets , 2016, Nature Communications.

[23]  C. Porta,et al.  Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.

[24]  A. Sangoi,et al.  Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women , 2016, The American journal of surgical pathology.

[25]  A. Sangoi,et al.  Tuberous Sclerosis–associated Renal Cell Carcinoma: A Clinicopathologic Study of 57 Separate Carcinomas in 18 Patients , 2014, The American journal of surgical pathology.

[26]  P. Argani,et al.  Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas. , 2013, Human pathology.

[27]  O. Hes,et al.  Renal hybrid oncocytic/chromophobe tumors - a review. , 2013, Histology and histopathology.

[28]  P. Argani,et al.  Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas , 2011, The American journal of surgical pathology.

[29]  Z. Gatalica,et al.  Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases , 2010, Virchows Archiv.

[30]  L. Galmiche,et al.  Hybrid tumour ‘oncocytoma‐chromophobe renal cell carcinoma’ of the kidney: a report of seven sporadic cases , 2009, BJU international.

[31]  K. Mai,et al.  Hybrid chromophobe renal cell neoplasm. , 2005, Pathology, research and practice.